do glp 1 cause pancreatic cancer Ozempic and Risk: Study Finds No Link GLP-1 peptide analogs for targeting

In the majority of the trials, the primary composite CV endpoint was a three-component major adverse CV event (MACE) outcome including CV-related mortality, non-fatal myocardial infarction (MI), and non-fatal stroke (the CVOT investigating lixisenatide, the ELIXA trial, also included time to the first occurrence of hospitalisation for unstable angina pectoris)

Statements made by doctors in the video misleadingly minimize and downplay the drugs boxed warning, contraindications, warnings and precautions and other common adverse events

Tirzepatide (Zepbound) was not included as that drug was only approved for obesity late in 2023

Fiber and hydration: Constipation is common with GLP-1s

Research gaps include appropriate patient classification, cost-effectiveness across healthcare systems, and established methodologies for developing applications